Empagliflozin not only decreases blood glucose levels, but also can be used to treat
heart failure (HF).
1
,2
A study suggested that empagliflozin 25 mg is preferable to 10 mg for patients with
HF with reduced ejection fraction.
3
However, it was unclear if there are differences in the effects of 10 mg and 25 mg
of empagliflozin on the outcomes of patients with HF with preserved ejection fraction
(HFpEF). The main aim of this study was to compare the efficacy of 10 mg and 25 mg
of empagliflozin in patients with HFpEF.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cardiovascular and renal outcomes with empagliflozin in heart failure.N Engl J Med. 2020; 383: 1413-1424
- Empagliflozin in heart failure with a preserved ejection fraction.N Engl J Med. 2021; 385: 1451-1461
- Different doses of empagliflozin in patients with heart failure with reduced ejection fraction.Int Heart J. 2022; 63: 852-856
Article info
Publication history
Published online: January 25, 2023
Accepted:
January 20,
2023
Received:
January 3,
2023
Publication stage
In Press Journal Pre-ProofFootnotes
See page xxx for disclosure information.
Identification
Copyright
© 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Is it time to relitigate SGLT2 Inhibitor dose for heart failure?Canadian Journal of Cardiology
- PreviewOver the past 40 years, we have observed the introduction of several medical therapies for heart failure with reduced ejection fraction (HFrEF). More recently, effective medical therapy (Goal Directed Medical Therapy, or GDMT)for patients suffering from heart failure with preserved ejection fraction (HFpEF) has been identified in the form of sodium/glucose cotransporter 2 inhibitors (SGLT2 inhibitors)(1). There has also been recognition that timely and aggressive GDMT titration to target doses leads to better outcomes(2).
- Full-Text
- Preview
